Contact this trialFirst, we need to learn more about you.
Orexin Receptor Antagonist
Suvorexant for Cushing's Syndrome
Recruiting1 awardPhase 2 & 3
Wernersville, Pennsylvania
This trial will determine if the orexin 1 / 2 receptor antagonist suvorexant decreases sleep disturbance and drug craving in patients with substance use disorders (SUDs), and if it has the potential to reduce relapse rates.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.